Literature DB >> 1866474

CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium.

J P Smith1, S T Kramer, T E Solomon.   

Abstract

The growth responses of six human pancreatic cancer cell lines (SW-1990, PANC-1, MIA PaCa-2, BxPC-3, RWP-2 and CAPAN-2) to cholecystokinin (CCK) were evaluated in serum-free medium (SFM). In each experiment cells were initially plated in media containing fetal calf serum (FCS) grown for 48-72 h, and then washed with saline. Cells were incubated for an additional 72 to 96 h in medium devoid of FCS in the absence (control) or presence of synthetic CCK analogue (Thr4,Nle7)CCK9 (10(-13) to 10(-9) M), or CCK8 (10(-12) to 10(-9) M), or CCK39 (10(-12) to 10(-9) M). Viable cell counts were performed with a hemocytometer. Growth of each cell line was stimulated in the presence of CCK in serum-free medium, although the magnitude of responses differed. The concentrations of (Thr4,Nle7)CCK9 which stimulated the greatest increase in cell counts as compared to controls for each cell line were: SW-1990, 39% (10(-12) M, P less than 0.05); PANC-1, 45% (10(-9) M, P less than 0.005); MIA PaCa-2, 42% (10(-12) M, P less than 0.005); BxPC-3, 32% (10(-13) M, P less than 0.05); RWP-2, 37% (10(-11) M, P less than 0.005). Maximal response to CCK8 occurred at the 10(-9) M dose for each cell line: MIA PaCa-2, 40% (P less than 0.025); PANC-1, 85% (P less than 0.001); RWP-2, 68% (P less than 0.001) and CAPAN-2, 52% (P less than 0.001). The maximal increase in cell count with CCK39 ranged from 44-74% and occurred with either 10(-11) or 10(-10) M. CCK8 in SFM also stimulated cell growth as well as or better than FCS alone in three out of four pancreatic cell lines.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1866474     DOI: 10.1016/0167-0115(91)90027-e

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  26 in total

1.  Role of endogenous cholecystokinin on growth of human pancreatic cancer.

Authors:  Gail L Matters; Christopher McGovern; John F Harms; Kevin Markovic; Krystal Anson; Calpurnia Jayakumar; Melissa Martenis; Christina Awad; Jill P Smith
Journal:  Int J Oncol       Date:  2010-12-24       Impact factor: 5.650

Review 2.  Cholecystokinin and pancreatic cancer: the chicken or the egg?

Authors:  Jill P Smith; Travis E Solomon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

Review 3.  Clinical uses of gut peptides.

Authors:  J Geoghegan; T N Pappas
Journal:  Ann Surg       Date:  1997-02       Impact factor: 12.969

Review 4.  On the role of cholecystokinin in pancreatic cancer.

Authors:  M K Herrington; T E Adrian
Journal:  Int J Pancreatol       Date:  1995-04

5.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

6.  Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat.

Authors:  Gail L Matters; Timothy K Cooper; Christopher O McGovern; Evan L Gilius; Jiangang Liao; Brian M Barth; Mark Kester; Jill P Smith
Journal:  Dig Dis Sci       Date:  2014-05-11       Impact factor: 3.199

7.  Cholecystokinin analog, JMV-180, stimulates growth of human pancreatic cancer.

Authors:  I R Swift; J P Smith
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

8.  Carcinoid syndrome misdiagnosed as a malabsorptive syndrome after biliopancreatic diversion.

Authors:  E M López-Tomassetti Fernandez; I Arteaga González; H Díaz Luis; A Carrillo Pallarés
Journal:  Obes Surg       Date:  2007-07       Impact factor: 4.129

Review 9.  Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.

Authors:  W E Fisher; P Muscarella; L G Boros; W J Schirmer
Journal:  Int J Pancreatol       Date:  1998-12

10.  Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.

Authors:  Jill P Smith; Timothy K Cooper; Christopher O McGovern; Evan L Gilius; Qing Zhong; Jiangang Liao; Alfredo A Molinolo; J Silvio Gutkind; Gail L Matters
Journal:  Pancreas       Date:  2014-10       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.